An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 18, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Multiple Myeloma

Interventions

DRUG

NKG2D Chimeric Antigen Receptor NK Cell Injection

Administer KN1102 cell injection three times on day 0, day 7, and day 14, respectively.

Trial Locations (1)

Changzhou Second People's Hospital, Changzhou

All Listed Sponsors

lead

Changzhou No.2 People's Hospital

OTHER

NCT06379451 - An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma | Biotech Hunter | Biotech Hunter